Versant Vantage I, L.p. - Net Worth and Insider Trading
Versant Vantage I, L.p. Net Worth
The estimated net worth of Versant Vantage I, L.p. is at least $13 Million dollars as of 2024-11-13. Versant Vantage I, L.p. is the 10% Owner of Repare Therapeutics Inc and owns about 3,544,862 shares of Repare Therapeutics Inc (RPTX) stock worth over $12 Million. Versant Vantage I, L.p. is also the 10% Owner of Aprea Therapeutics Inc and owns about 142,633 shares of Aprea Therapeutics Inc (APRE) stock worth over $489,231. Details can be seen in Versant Vantage I, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Versant Vantage I, L.p. has not made any transactions after 2022-06-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Versant Vantage I, L.p.
Versant Vantage I, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Versant Vantage I, L.p. owns 9 companies in total, including Aligos Therapeutics Inc (ALGS) , Black Diamond Therapeutics Inc (BDTX) , and Pandion Therapeutics Inc (PAND) among others .
Click here to see the complete history of Versant Vantage I, L.p.’s form 4 insider trades.
Insider Ownership Summary of Versant Vantage I, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ALGS | Aligos Therapeutics Inc | 2020-10-15 | 10 percent owner |
| BDTX | Black Diamond Therapeutics Inc | 2020-01-29 | 10 percent owner |
| PAND | Pandion Therapeutics Inc | 2020-07-21 | 10 percent owner |
 | | 2022-06-03 | 10 percent owner |
| | 2020-05-18 | 10 percent owner |
| | 2020-02-27 | 10 percent owner |
| | 2019-10-30 | 10 percent owner |
| | 2021-06-23 | 10 percent owner |
| | 2023-09-14 | 10 percent owner |
Versant Vantage I, L.p. Latest Holdings Summary
Versant Vantage I, L.p. currently owns a total of 2 stocks. Among these stocks, Versant Vantage I, L.p. owns 3,544,862 shares of Repare Therapeutics Inc (RPTX) as of June 3, 2022, with a value of $12 Million and a weighting of 96.2%. Versant Vantage I, L.p. also owns 142,633 shares of Aprea Therapeutics Inc (APRE) as of October 7, 2019, with a value of $489,231 and a weighting of 3.8%.
Latest Holdings of Versant Vantage I, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RPTX | Repare Therapeutics Inc | 2022-06-03 | 3,544,862 | 3.50 | 12,389,293 |
| APRE | Aprea Therapeutics Inc | 2019-10-07 | 142,633 | 3.43 | 489,231 |
Holding Weightings of Versant Vantage I, L.p.
Versant Vantage I, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Versant Vantage I, L.p. has made a total of 2 transactions in Repare Therapeutics Inc (RPTX) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Repare Therapeutics Inc is the sale of 750,000 shares on June 3, 2022, which brought Versant Vantage I, L.p. around $9 Million.
According to the SEC Form 4 filings, Versant Vantage I, L.p. has made a total of 0 transactions in Aprea Therapeutics Inc (APRE) over the past 5 years. The most-recent trade in Aprea Therapeutics Inc is the acquisition of 16,667 shares on October 7, 2019, which cost Versant Vantage I, L.p. around $5 Million.
Insider Trading History of Versant Vantage I, L.p.
- 1
Versant Vantage I, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Versant Vantage I, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Versant Vantage I, L.p. is 57.13%. GuruFocus also compares Versant Vantage I, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Versant Vantage I, L.p. within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Versant Vantage I, L.p.'s insider trading performs compared to the benchmark.
Performance of Versant Vantage I, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -6.37 | | | | | |
| Relative Return to S&P 500(%) | -10.52 | | | | | |
Versant Vantage I, L.p. Ownership Network
Ownership Network List of Versant Vantage I, L.p.
Ownership Network Relation of Versant Vantage I, L.p.
Versant Vantage I, L.p. Owned Company Details
What does Aligos Therapeutics Inc do?
Who are the key executives at Aligos Therapeutics Inc?
Versant Vantage I, L.p. is the 10 percent owner of Aligos Therapeutics Inc. Other key executives at Aligos Therapeutics Inc include 10 percent owner Roche Holding Ltd , 10 percent owner Roche Finance Ltd , and Chief Medical Officer Matthew W. Mcclure .
Aligos Therapeutics Inc (ALGS) Insider Trades Summary
Over the past 18 months, Versant Vantage I, L.p. made no insider transaction in Aligos Therapeutics Inc (ALGS). Other recent insider transactions involving Aligos Therapeutics Inc (ALGS) include a net purchase of 7,933,601 shares made by Carole Nuechterlein ,
In summary, during the past 3 months, insiders sold 0 shares of Aligos Therapeutics Inc (ALGS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aligos Therapeutics Inc (ALGS) were sold and 317,344 shares were bought by its insiders, resulting in a net purchase of 317,344 shares.
Aligos Therapeutics Inc (ALGS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aligos Therapeutics Inc Insider Transactions
Versant Vantage I, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Versant Vantage I, L.p.. You might contact Versant Vantage I, L.p. via mailing address: One Sansome, Suite 1650, San Francisco Ca 94104.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
